Contact Us |
Participating Transplant Centers are required to:
a. Select disease option for Multiple myelomab. Indicate Yes for question 2; Has the recipient signed an IRB / Ethics Committee-approved consent form for participation in the study?c. Indicate Yes for question 4; Does the recipient have Medicare coverage?
a. Indicate Yes for question 6; Is the Recipient participating in a clinical trial?b. Select RCI BMT for question 7; Select Study Sponsor.c. Select 17-CMS-MM for question 9; Select the Study ID Numberd. If Research Database consent signed, select Yes
a. Indicate disease classification for question 232; eligible classifications includei. MM-IgGii. MM-IgAiii. MM-IgDiv. MM-IgEv. MM-IgM (not Waldenstrom)vi. MM-light chain onlyvii. MM-non secretoryb. Indicate response for Durie-Salmon staging question 235c. Indicate response for I.S.S. staging question 239; patient must be stage II or stage III for at least one of the staging questions.
i. MM-IgGii. MM-IgAiii. MM-IgDiv. MM-IgEv. MM-IgM (not Waldenstrom)vi. MM-light chain onlyvii. MM-non secretory
This study uses the existing research observational database of the CIBMTR to collect data requested by CMS as part of its payment policy. Participants who wish to receive coverage from CMS must sign the existing IRB approved CMS consent for the research observational database. Additional protocol or consent forms are not required for this study.
The Research Database protocol, consent form, and CIBMTR/NMDP IRB approvals, can be found on the Observational Database and Protocol and Consent Forms page.
For clinical research questions contact: Sue Logan, CIBMTR-Minneapolisslogan@nmdp.org 763-406-8575
For Medicare claims questions contact: NMDP/Be The Match Payer Policy firstname.lastname@example.org
Coding and Billing:
There is not a prior authorization process for Medicare CED studies. The patient must be clinically eligible for the study and have their transplant at a participating center. When the claim is filed, it must have an approved ICD-10 Diagnosis code and National Clinical Trial number (NCT03127761) listed on the claim.
View initial coding guidance information.
Study Reference Materials: